Skip to main content
Medigene AG logo

Medigene AG — Investor Relations & Filings

Ticker · MDG1 ISIN · DE000A40ESG2 LEI · 391200I33JD2DKZGDX06 F Professional, scientific and technical activities
Open in API
Filings indexed 114 across all filing types
Latest filing 2022-12-22 Report Publication Anno…
Country DE Germany
Listing F MDG1

About Medigene AG

https://medigene.com/

Medigene AG is a biotechnology company that develops T-cell receptor (TCR)-guided immunotherapies for the treatment of cancer. The company utilizes its proprietary End-to-End platform to discover and develop optimized 3S (sensitive, specific, safe) TCRs. These TCRs are designed for application across various therapeutic modalities, including TCR-T cell therapies, TCR-T cell engagers, and TCR-natural killer cell therapies, targeting different forms of cancer. A key clinical program is MDG1015, a third-generation TCR-T therapy targeting the NY-ESO-1/LAGE-1a antigen, which is enhanced with a PD1-41BB costimulatory switch protein. As of August 2025, the company is undergoing insolvency proceedings.

Recent filings

Filing Released Lang Actions
Hinweis auf Halbjahresfinanzbericht vom 01.01.2023 bis zum 30.06.2023
Report Publication Announcement Classification · 100% confidence The document is a short notification (1025 characters) announcing the availability of a half-year financial report. It explicitly states 'Hinweis auf Halbjahresfinanzbericht' (Notice regarding half-year financial report) and provides a link to where the report can be found. Per the 'Menu vs Meal' rule, since this is an announcement of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2022-12-22 German
Hinweis auf Jahresfinanzbericht vom 01.01.2022 bis zum 31.12.2022
Report Publication Announcement Classification · 99% confidence The document text is very short (1026 characters) and explicitly states that a financial report ('year report of the group 2022') 'shall be disclosed' and provides a link where it can be found ('Im Internet unter: https:/\/www.medigene.com\/investors-media\/reports-presentations'). The subject line is 'Hinweis auf Jahresfinanzbericht' (Notice of Annual Financial Report). This structure perfectly matches the definition of a Report Publication Announcement (RPA), which announces the availability of a report rather than being the report itself (like a 10-K or AR).
2022-12-22 German
Hinweis auf Halbjahresfinanzbericht vom 01.01.2023 bis zum 30.06.2023
Report Publication Announcement Classification · 98% confidence The document text is very short (1035 characters) and explicitly functions as a 'Hinweis' (Notice) regarding the disclosure of a financial report. It states: 'Medigene AG announces that the following financial reports shall be disclosed: half-year report of the group 2023'. It also specifies where and when the report will be available ('Im Internet am: 02.08.2023'). According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report is being published or made available points to a Report Publication Announcement (RPA), rather than the comprehensive report itself (which would be an IR). The report being announced is a 'half-year report', which typically corresponds to an Interim Report (IR), but this document is the *announcement* of that report.
2022-12-22 German
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2022 bis zum 30.06.2022
Interim / Quarterly Report Classification · 100% confidence The document is a 'Halbjahresfinanzbericht' (Half-Year Financial Report) for Medigene AG for the period 01.01.2022 to 30.06.2022. It contains a 'Konzern-Zwischenlagebericht' (Group Interim Management Report) and detailed descriptions of business development, clinical trials, and technology platforms. As it is a comprehensive financial report for a period shorter than a full fiscal year, it falls under the 'Interim / Quarterly Report' category. H1 2022
2022-08-03 German
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
Management Reports Classification · 95% confidence The document is a detailed management report (Geschäftsverlauf) for Medigene AG for the fiscal year 2021. It covers business overview, market environment, corporate events, and detailed research and development activities. It contains substantive management analysis and business performance data, which aligns with the definition of a Management Report (MDA). FY 2021
2022-05-02 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2020 bis zum 31.12.2020
Audit Report / Information Classification · 98% confidence The document is a German 'Jahresabschluss' (Annual Financial Statement) for the fiscal year 2020, including a balance sheet ('Bilanz') and detailed accounting notes ('sonstige Berichtsbestandteile'). It follows the structure of a statutory annual financial report for a German company (Mediget AG). While it is not a full 10-K (which is a specific US SEC filing), it serves the function of an annual report. Given the provided categories, '10-K' is the standard classification for comprehensive annual financial reports, even for non-US entities in this taxonomy. FY 2020
2022-03-25 German

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.